Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report outlays ...

In addition to AIS, DiaMedica (DMA.V) (DMCAF) is also developing DM199 for the treatment of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) or Diabetic nephropathy (DN) is one of the most ...

A new study by Bernhard Dumoulin, Katalin Susztak and colleagues provides insights into the spatial organization of cells in diabetic kidney disease (DKD) and identifies a tertiary lymphoid structure ...

Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial. C. Ola Landgren, MD, PhD: The once-weekly and twice-weekly ...

An overview of the FIGARO-DKD trial, which evaluated cardiovascular and renal outcomes in patients with type 2 diabetes and CKD treated with finerenone. Rajiv Agarwal, MD, MS: The FIGARO-DKD trial is ...

New research suggests that a common second-line blood pressure treatment may not be as kidney-friendly as previously assumed ...

BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership, has announced the launch of a 5-year project with the aim to improve prevention and management ...

In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the ...

Diabetic kidney disease (DKD) is a serious complication of diabetes. Substantial between-patient variation exists in the progression and severity of DKD; however, the factors that contribute to this ...